Clinical trials: Human Papilloma Virus
HIV Infections
A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017
Phase IV, open, multicenter and single-arm clinical trial designed to evaluate the immunogenicity of the HPV9v vaccine in men with HIV infection (HIV +) who have sex with men (MSM)
- Trial name
- GESIDA10017 (NCT03626467)
- Testing
- HPV9v
- Where
- 3 sites in Spain
- Volunteers
- 158 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections, Anal Cancer
Screening for HIV-Associated Anal Cancer
Cancer of the anus occurs at very high rates in young men with HIV and is caused by a virus called human papillomavirus (HPV). Anal cancer has increased during the HIV epidemic despite effective therapies for HIV.
- Conditions
- HIV Infections, Anal Cancer, Anal Dysplasia, Papillomavirus Infections
- Trial name
- TRACE (NCT00188292)
- Where
- Canada
- Volunteers
- 401 people
- Sponsor
- University Health Network, Toronto
Cervical Cancer
Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia
Human papillomavirus (HPV) of high-risk genotype is a necessary risk factor in development of cervical cancer. There is a vaccine available to prevent cervical lesions associated with high-risk HPV genotypes 16 and 18.
- Trial name
- HPV-cancer (NCT01385436)
- Where
- Croatia
- Volunteers
- 400 people
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Cervical Cancer Screening, Human Papilloma Virus
Developing and Implementing HPV SCREENED
This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED).
- Trial name
- NCT07657104
- Testing
- HPV Self-collection in the ED
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
HPV Infections
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
- Trial name
- NCT03085381
- Testing
- HPV vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Papilloma Viral Infection, CIN1
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential…
- Conditions
- Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion
- Trial name
- NCT05916911
- Testing
- Glizigen
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities
The goal of this observational study is to assess the five-year incidence of histologically confirmed cervical cancer among women who test positive for human papillomavirus (HPV) with low-grade cytological abnormalities, to…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
- Trial name
- NCT07259616
- Volunteers
- 46,079 people
- Sponsor
- Gynaecologisch Oncologisch Centrum Zuid
HPV
Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers
This will enroll 300 mothers of teenage girls and boys to identify barriers to HPV vaccination among low-income, African-American teens.
- Trial name
- NCT00680147
- Testing
- brief informational intervention to promote HPV vaccine acceptance
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Syracuse University
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Papillomavirus Infections
Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
- Trial name
- NCT00117884
- Testing
- 851B
- Where
- 23 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Takeda
Parents, Parent-Child Relations
Development and Psychometric Testing of HPV Knowledge Scale
The aim of this study is to develop and conduct psychometric testing of a new scale, the Human Papillomavirus Knowledge Scale (HPV-KS), particularly designed to assess HPV knowledge among parents of school-age children in…
- Trial name
- NCT06466252
- Testing
- Psychometric Group
- Where
- Indonesia
- Volunteers
- 673 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University
Warts
Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts
The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.
- Trial name
- NCT04399577
- Testing
- Candida antigen
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Zagazig University
HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis
Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women
Most genital infections by human papillomaviruses (HPV) are asymptomatic or benign and clear within a few months or years. There infections are much less studies than chronic infections, even though they represent the main…
- Conditions
- HPV Genital Infection (Primary Condition Studied), Bacterial Vaginosis, Chlamydiae Infection
- Trial name
- PAPCLEAR (NCT02946346)
- Testing
- vaginal sampling
- Where
- France
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Human Papillomavirus Infection, HPV Vaccines
The Role of Cyberchondria Severity in the Relationship Between HPV Awareness and Vaccination Attitudes in Adult Women
Human papillomavirus (HPV) is a prevalent sexually transmitted infection linked to nearly all cases (99%) of cervical cancer. Prophylactic HPV vaccination is effective in preventing these cancers, complemented by HPV screening…
- Conditions
- Human Papillomavirus Infection, HPV Vaccines, Cyberchondria, Awareness
- Trial name
- NCT06800456
- Where
- Turkey (Türkiye)
- Volunteers
- 337 people
- Sponsor
- Acibadem University
Genital Human Papilloma Virus Infection
AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections
This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection.
- Trial name
- NCT01654822
- Testing
- topical application cervical spray, topical spray on the cervix, cervical swab with Cervex-Brush-Combi at T0
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Cesa Projects International
CIN - Cervical Intraepithelial Neoplasia, HPV
Multiple Human Papillomavirus Infections in the Development of CIN
Multiple infections of high-risk genotypes of Human Papillomavirus (HR-HPV) in patients with abnormal cervical cytological or histological findings are detectable in a percentage ranging from 20% to 50% of cases.
- Conditions
- CIN - Cervical Intraepithelial Neoplasia, HPV, HPV Vaccines
- Trial name
- HPV dysplasia (NCT06862102)
- Testing
- HPV vaccine
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Intraepithelial Neoplasia, Cervical Cancer
Impact of HPV Vaccine On The Prevalence Of HPV In Norway
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Oropharyngeal Cancer
- Trial name
- NCT02934724
- Testing
- Self sample from vagina, Self sample from the oral cavity, Questionnaire
- Where
- Norway
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cervical Intraepithelial Neoplasia-II, High Risk Human Papillomavirus
Effect of Honey For CIN II
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
- Trial name
- HoneyForCINII (NCT06219018)
- Testing
- Medical grade honey formulation (MGH) (L-Mesitran®)
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
Cervical Intraepithelial Neoplasia
DC Vaccines Targeting HPV16/18 E6/E7 Protein to Regress CINI/CIN2
To establish therapeutic dendritic cell (DC) vaccines targeting HPV 16/18 E6/E7 protein to block the progression of CIN1/CIN2 to cervical cancer and evaluate the safety and efficacy of the vaccines.
- Trial name
- NCT03870113
- Testing
- Vaccinated group
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital